ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1880

Global Gene Expression Profiles Reveal Genetic Signatures Of Kawasaki Disease and Disease Outcome

Long Truong Hoang1, Chiea Chuen Khor2, Ahmad Nazri Mohamed Naim3, Ling Ling3, Chisato Shimizu4, Martin L. Hibberd1 and Jane C. Burns4, 1Infectious Diseases, Genome Institute of Singapore, Singapore, Singapore, 2Human Genetics, Genome Institute of Singapore, Singapore, Singapore, 3Genome Institute of Singapore, Singapore, Singapore, 4Pediatrics, UC San Diego, School of Medicine, La Jolla, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Gene Expression and Kawasaki disease

  • Tweet
  • Email
  • Print
Session Information

Title: Genetics and Genomics of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Kawasaki Disease (KD) is a self-limited vasculitis of unknown etiology that predominantly affects children younger than 5 years. The inflammation associated with KD affects the arterial wall and leads to coronary artery aneurysms (CAA) in 25% of untreated KD children, making KD the most common cause of acquired heart disease in children in developed countries. Genetic predispositions are thought to influence the risk of aneurysm formation, and several gene expression profiling studies for KD were performed to describe KD-specific signatures. However, the lack of power due to limited sample size precluded definitive identification of transcriptomic signatures specific to KD. In this study, we aim to identify the gene expression signatures associated with acute KD by investigating the global gene expression profiles in large number of samples collected in paired-blood samples from acute and convalescent phases. We also investigated the transcript abundance in patients with different IVIG treatment status and different CAA outcomes.

Methods: Illumina gene expression microarray was used to characterize gene expression profiles of 171 KD patients with paired blood samples from the acute and convalescent phase of KD. Quantitative RT-PCR was used to validate the findings of the microarray. A detailed clinical and hematological data was also collected for all the patients. A generalized linear model was used to indentify differentially abundant transcripts between acute and convalescent samples, as well as between IVIG response status and CAA outcomes.

Results: Our data suggest that the complement and coagulation cascades, Toll-like receptor signaling and innate immune related responses were the most prominent pathways that were up-regulated in acute KD patients, while CD8 T cell receptor pathway such was less abundant in acute patients. Toll-like receptors (TLR2, 5 and 8), FCGR1 (A and B), FCRG2 (A and B), CD3, CD4, CD8 and CD28 were amongst the most significant transcripts. We also observed and validated 24 transcripts that were differentially expressed between IVIG responsive and IVIG-resistant KD patients which could play a pivotal role in the disease pathogenesis. These include LILRA5, IL18R1, IRAK3, SORT1 and BMX.   

Conclusion: We proposed the potential genetic signatures of acute KD and signatures of IVIG treatment outcomes. The functions of these markers will be further discussed.


Disclosure:

L. T. Hoang,
None;

C. C. Khor,
None;

A. N. Mohamed Naim,
None;

L. Ling,
None;

C. Shimizu,
None;

M. L. Hibberd,
None;

J. C. Burns,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/global-gene-expression-profiles-reveal-genetic-signatures-of-kawasaki-disease-and-disease-outcome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology